News

Medical device company Boston Scientific recently launched the LUX-Dx Insertable Cardiac Monitor (ICM) System in Europe. The ICM System is a long term diagnostic device that is inserted under patients’ skin, with the aim of detecting arrhythmias which are associated with certain conditions, such as AF (atrial fibrillation) and cryptogenic stroke. The Lux-Dx has been designed with a dual stage algorithm which detects and verifies potential arrythmias, before sending an alert to clinicians. This algorithm can be remotely programmed to identify atrial flutter, bradycardia episodes, rhythm pause and tachycardia episodes, allowing the device to recognise arrhythmias whenever specified parameters or thresholds are exceeded.

Additionally, the tech also has the potential for supporting patient follow-up of electrophysiology procedures via remote monitoring, which could play an essential role when it comes to supporting the efficiency of medical teams. This remote patient monitoring should help clinicians in prioritising care when hospital teams are particularly under pressure, as they can provide guidance on triaging each patient.

Lydia Bradley, CRM service lead physiologist & ACP at Royal Wolverhampton Hospitals NHS Trust, England, said: “We had the opportunity to be one of the first in the UK to implant the LUX-Dx ICM. Signals seen so far at implant have been providing great sensing and amplitude of P waves as well as fibrillation waves. Patients have been happy and confident with the ease of setup and use of their patient phone. Ease of use, clarity of the information and intuitive platform are invaluable in helping us make prompt decisions.”

After LUX-Dx is implanted, patients are given a mobile device which contains the pre-installed MyLUX app, which can connect through Bluetooth to their ICM device. Information from the app is transmitted either daily, or when required, to the LATITUDE Clarity Data Management System, which gives physicians and care teams instant access to vital knowledge.

Angelo De Rosa, vice president and general manager EMEA, Rhythm Management, Boston Scientific, said: “We are excited to expand our reach into the cardiac diagnostic field with the LUX-Dx ICM System. Signal quality, dual-stage algorithm and remote programming will further unlock the potential of remote patient monitoring technology in Europe and reinforce the therapy offerings we can provide to physicians, from diagnosis to treatment.” The Lux-Dx ICM System has achieved CE Mark within Europe, as well as US Food and Drug Administration (FDA) 510(k) clearance.


© Boston Scientific Corporation